BioCryst Pharmaceuticals Inc. said Wednesday its potential gout drug met key goals in the first part of a midstage study.
The drug candidate, called BCX4208, met goals of reducing serum uric acid levels in the 21-day study, involving three different doses. The first part of the study tested 60 gout patients.
Gout is a painful inflammatory condition caused by elevated levels of uric acid in the blood.
The second part of the midstage study is now under way, the company said. The company expects to complete the studies in 2010 and use the results to define dosing levels for further development.
Shares of BioCryst rose 90 cents, or 13 percent, to $7.93 in morning trading. The stock has traded between $2.36 and $13.47 over the last 52 weeks.